TerminatedPhase 4

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Stopped: difficulty of enrolling patients

37 participantsStarted 2006-05

Plain-language summary

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 18 years; * CACG (Chronic Angle Closure Glaucoma) ≥ 1eye * have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes * clinical stability of VA (Visual Acuity) and optic nerve throughout the study Exclusion Criteria: * Abnormality restricts exam of the fundus or anderior chamber * conjunctivitis, keratitis or uveitis * unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks * ocular surgery prior to the study

What they're measuring

Mean IOP (Intraocular Pressure)

Timeframe: Screening: Week 12; (At 9 am and 4 pm time points)

Trial details

NCT IDNCT00758342

SponsorAlcon Research

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-03

Results submitted2009-09-10

View on ClinicalTrials.gov More Intraocular Pressure trials